Changing Epidemiology of KPC Producing Klebsiella pneumoniae in Argentina: Emergence of Hypermucoviscous ST25 and High Risk Clone ST307 by Cejas, Daniela et al.
Accepted Manuscript
Title: Changing Epidemiology of KPC Producing Klebsiella
pneumoniae in Argentina: Emergence of Hypermucoviscous
ST25 and High Risk Clone ST307
Authors: Daniela Cejas, Alan Elena, Daiana Guevara Nuñez,
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Highlights  
 Change in the epidemiology of KPC- K. pneumoniae isolates in Argentina 
 Dissemination of resistant and hypermucoviscous clone: KPC- K. pneumoniae 
ST25  
 First detection of K. pneumoniae ST307 and blaKPC-3 in Argentina 
 mgrB inactivation in colistin resistant KPC- K. pneumoniae isolates 
 
Abstract: 
Objectives: To assess the epidemiological features of 76 KPC producing K. 
pneumoniae isolates (KPC-Kp) recovered in 3 hospitals of Buenos Aires, Argentina, 
during 2015-2017. 
Methods: Antimicrobial susceptibilities were determined according to CLSI. 
Molecular typing of KPC-Kp was performed by PFGE-XbaI and MLST. Plasmid 
encoded genes involved in carbapenem, fosfomycin and colistin resistance were 
detected by PCR and sequencing. Also mgrB inactivation was investigated in those 
colistin resistance isolates. Genetic platforms involved in horizontal spread of blaKPC 
were investigated by PCR mapping.   
Results: Besides β-lactams, high resistance rates were observed for gentamycin, 











26% of the isolates while 42% corresponded to ST25. The other isolates were 
distributed in a diversity of lineages such as ST11 (10.5%), ST392 (10.5%), ST307, 
ST13, ST101, ST15 and ST551. blaKPC-2 was detected in 75/76 isolates, and one 
ST307 isolate harbored blaKPC-3. Tn4401 was identified as the genetic platform for 
blaKPC in epidemic lineages such as ST258 and ST307. However in ST25 and ST392, 
usually no related to blaKPC, it was identified blaKPC -bearing non- Tn4401 element. 
Alterations in mgrB were detected in 7 out of 11 colistin resistant isolates. 
Conclusions: Despite previous reports in Argentina, ST258 is no longer the absolute 
clone among KPC-Kp isolates. In the present study, the dissemination of more 
virulent lineages such as the hypermucoviscous ST25 was detected. Even more, it 
was noticed for the first time in our region the emergence of the high risk clone 
ST307 and also the occurrence of blaKPC-3. 
 




Carbapenem resistant isolates, mainly those producing K. pneumoniae 
carbapenemase (KPC), are worldwide spread and are associated with high morbidity 
and mortality rates [1]. KPC- K. pneumoniae global expansion has been associated 
with the dissemination of epidemic clones, especially the dominant strain 
K. pneumoniae sequence type (ST) 258 and related strains of clonal complex (CC) 











between ST11 and ST442 [3-5]. This clone emerged in Argentina in 2010 becoming 
the prevalent ST and achieving epidemic status in many settings [6, 7]. CC258 
includes multidrug resistant microorganisms, displaying resistance to all β-lactams, 
aminoglycosides, quinolones, trimethoprim and sulfonamides [2]. Singularly, ST258 
is reported to be mildly virulent. The high mortality rates attributed to this clone may 
be explained, at least in part, by the low efficacy of the antimicrobials used against 
KPC-K. pneumoniae infections and the severity of the underlying conditions of the 
patients [3]. It is highly susceptible to serum killing and phagocytosis, and lacks 
typical K. pneumoniae virulence factors such as aerobactin, K1, K2 and K5 capsular 
genes, and the regulator gene of the mucoid phenotype, rmpA [5, 8].  
However, in the recent years new strains of KPC-K. pneumoniae have emerged 
internationally, which correspond to hypervirulent clones that have acquired 
extensively drug resistance markers [9, 10]. 
Transposon Tn4401 constitutes the most frequent genetic context of blaKPC, and is 
considered the origin of acquisition and dissemination of this marker. Tn4401 is 
approximately 10 kb in size, delimited by two 39-bp imperfect inverted repeat 
sequences. It harbors two insertion sequences flanking blaKPC, ISKpn6 and ISKpn7, in 
addition to a transposase and resolvase genes [5, 11]. Moreover, blaKPC-bearing non- 
Tn4401 elements have been recognized including the integration of a Tn3-based 
transposon and a partial Tn4401 structure (ORF order: Tn3-transposase, Tn3-
resolvase, ISKpn8, blaKPC and ISKpn6). Even, variants in the upstream blaKPC region, 
lacking the Tn3-transposase and its resolvase and displaying a partial fragment of 











The aim of this study was to assess the epidemiological features of KPC-K. 
pneumoniae in order to understand the ongoing evolution of carbapenem resistance in 
our region.    
 
2. Material and Methods 
2.1 Bacterial isolates and antimicrobial susceptibility testing  
Seventy six non repetitive K. pneumoniae isolates, positive in the double-disk 
synergy test using phenyl boronic acid (300 µg) and carbapenem containing disks 
were included in this study. These isolates were recovered from inpatients at 3 
hospitals in Buenos Aires during 2015-2017. A total of 374 K. pneumoiae isolates 
were recovered from inpatients during the studied period, being 81(22 %) of them 
carbapenem resistant and 76 (20 %) KPC producers. These resistant isolates were 
delivered to the Laboratorio de Resistencia Bacteriana in an encrypted way to 
preserve the identity of the patients.  
Susceptibilities to ampicillin, ampicillin-sulbactam, piperacillin-tazobactam, 
ceftazime, ceftriaxone, imipenem, meropenem, gentamycin, amikacin, ciprofloxacin, 
levofloxacin and trimethoprim-sulfamethoxazole were assessed by automated 
systems. Colistin and tygecycline minimum inhibitory concentrations (MICs) were 
determined by broth microdilution method and agar dilution method was performed 
to determine the fosfomycin susceptibility. Antimicrobial susceptibilities were 
interpreted using the CLSI breakpoints, except for colistin and tigecycline where 













2.2 Molecular detection of antimicrobial resistance genes 
The presence of the most prevalent carbapenemase genes (blaKPC, blaVIM, blaIMP, 
blaNDM and blaOXA-48-like) was investigated by multiplex-PCR using specific primers 
[14]. Plasmidic mcr-1 and mcr-2, and fosA3, fosA4 and fosC2 were screened by PCR 
in those isolates which displayed resistance to colistin and fosfomycin, respectively 
[15, 16]. Colistin resistance mediated by mgrB inactivation was studied according to 
Cannatelli et al [17]. Complete blaKPC was amplified as previously described [18]. All 
amplicons were sequenced at external facilities (Macrogen Inc., Seoul, Korea) and 
analyzed using the BLAST program at NCBI (http://www.ncbi.nlm.nih.gov/BLAST).  
2.3 Molecular typing of K. pneumoniae isolates harboring blaKPC 
Clonal relationship was analyzed, for the 76 isolates, by PFGE after digestion of 
genomic DNA with XbaI and interpreted according to van Belkum et al. [19, 20]. 
MLST analysis was performed in representative isolates of each different pulsotype. 
STs were assigned amplifying and sequencing the following 7 housekeeping genes: 
gapA, infB, mdh, pgi, phoE, rpoB, tonB in accordance with 
http://bigsdb.web.pasteur.fr/klebsiella/.  
 
2.4 Analysis of genetic platforms carrying blaKPC-2 
Natural plasmids were extracted using the Kado & Liu extraction method [21]. The 
genetic context of blaKPC was studied by a PCR mapping approach in order to detect 
the Tn4401 structure and blaKPC-bearing non- Tn4401 elements, as previously 























Clinical features of KPC-K. pneumoniae isolates and main demographic data are 
shown in table 1. The incidence rate of KPC-K. pneumoniae was about 7.3 per 1000 
discharges, in these hospitals.  Most of the 76 isolates were recovered from urine and 
blood samples. Patients age ranged from 20 to 94 years (median age was 72 and 70 
for females and males, respectively), and the male to female ratio was 1.76. Although 
all patients presented underlying conditions, cancer and urinary tract diseases were 
the most common primary cause; 43.5 % of them were hospitalized in intensive care 
units and 87 % had received previous antibiotic treatment (Table 1).  
High resistance rates were detected for β-lactams, gentamycin, quinolones and 
trimethoprim-sulfamethoxazole (TMS) (Figure 1). All isolates were resistant to 
ampicillin, ampicillin-sulbactam, ceftazidime, ceftriaxone, 8/76 were intermediate 
and 68/76 were resistant to imipenem, while 4/76 and 72/76 isolates were 
intermediate and resistant to meropenem, respectively. blaKPC-2 carbapenemase gene 
was detected in 75 isolates while blaKPC-3 was harbored in the remaining. Fifteen % of 
the isolates (11/76) were resistant to colistin while 18% (14/76) were resistant to 
fosfomycin. The plasmidic resistance genes for colistin and fosfomycin were not 
detected. Alterations in mgrB locus were identified in 7/11 colistin resistant isolates: 
4 displayed ΔmgrB  and 3 exhibit mutations which were not previously described. 
Two isolates presented g85t mutation (D29Y), and the remaining presented g59a, 
rendering a premature stop (Table 2). 
The PFGE-XbaI analysis showed the presence of 18 different pulsotypes which were 











ST392 (n:8), ST307 (n:2), ST13 (n:1), ST101 (n:1), ST15 (n:1) and ST551 (n:1). 
Those isolates which belonged to ST258, ST307, ST101 and 4/8 ST11 presented the 
complete Tn4401 while those isolates which corresponded to ST25, ST392, ST13, 
ST15, ST551 and 1/8 ST11 presented ISKpn8 upstream blaKPC, as part of Tn3 (Tn3-
ISKpn8), and ISKpn6 downstream (Figure 2). Presence of ΔblaTEM upstream to blaKPC 
was not detected in any isolate. 
 
4. Discussion 
Even if previous studies performed in Argentina showed that KPC-K. pneumoniae 
dissemination corresponded to the propagation of a unique clone, ST258 [6, 7], today 
CC258 accounted for only 37% of the isolates (ST258 (26 %), ST11 (11%)). New 
lineages of KPC-K. pneumoniae were detected, and among them, a high proportion of 
isolates (42%) belonged to the emerging ST25, a virulent and hypermucoviscous 
clone which presents the capsular serotype K2. Interestingly, almost all ST25 isolates 
displayed susceptibility to amikacin. Reports on this ST from clinical samples are 
scarce; in China, Yao et al reported 1 clinical isolate of K. pneumoniae ST25 
recovered from a tracheal secretion, but this one was susceptible to carbapenems 
[10]. Also carbapenem susceptible K. pneumoniae ST25 has been described as cause 
of septicemia in neonate pigs, in England and Australia, being responsible for a total 
of 19 outbreaks in 16 piggeries and 2 outbreaks in 2 pig farms, respectively [22]. One 
NDM-1 producing K. pneumoniae ST25 isolate was recovered in Serbia in 2011 and 
5 KPC-2 producing K. pneumoniae ST25 isolates, causing invasive human infections, 











Furthermore, 10.5 % of the isolates corresponded to ST392, a lineage related to the 
dissemination of OXA-48 in Europe. Even though the emergence and spread of KPC-
2-K. pneumoniae ST392 was described in 2013, in China, this strain has been 
sporadically reported [25]. More recently, in 2017, KPC-3-K. pneumoniae ST392 was 
reported in Italy [26]. 
The remaining isolates were distributed in a diversity of lineages as ST13, ST15, 
ST101, ST551 and ST307. Singularly KPC-K. pneumoniae ST307 is recognized as a 
high risk clone which is being increasingly documented in several countries and is 
considered a candidate to become the worldwide epidemic clone [27-31]. Compared 
with the low virulent ST258, capsulated ST307 isolates show higher resistance to 
complement-mediated killing. Even more, ST307 clone harbors a cluster for 
glycogen synthesis which could provide an advantage allowing long term survival 
and growth in environments outside the host [31]. This high-risk clone has not been 
previously recognized in Argentina. The 2 isolates which belonged to this ST were 
recovered from different hospitals in 2017 and presented different non β-lactam 
susceptibility profiles. One of them presented blaKPC-2, and was susceptible to colistin 
and resistant to TMS. The other one harbored blaKPC-3, and was resistant to colistin 
and susceptible to TMS. This blaKPC allele has not been previously described in 
Argentina, it is worth highlighting that mutations in blaKPC-3 can conduce to KPC-3 
variants with significantly reduce ceftazidime-avibactam susceptibility [32].  
Two main blaKPC genetic platforms were identified. Except for ST11, each context 
could be associated with a particular ST. In accordance with the literature, the well-











and ST307), while Tn3-ISKpn8 was detected in those STs not usually related to 
blaKPC, as ST25 and ST392 [4].  
The colistin plasmid encoded mechanisms do not seem to have an epidemiological 
impact in K. pneumoniae. Although in this study, mutations in mgrB locus were 
detected in many of the colistin resistant isolates, changes in other loci involved in 
upregulation of the Pmr system, which is responsible for modification of the 













This study describes the changing epidemiology of KPC-K. pneumoniae lineages in 
clinical settings. The almost absolute prevalence of ST258 in our region is being 
replaced by the dissemination of more virulent lineages such as ST25 and ST11, and 
the worrisome emergence of the high-risk clone ST307. Even more, we report for the 
first time in Argentina, the detection of ST307- blaKPC-3-K. pneumoniae. The 
dichotomy between carbapenem resistant K. pneumoniae and hypervirulent K. 
pneumoniae has been blurred by the emergence of carbapenem resistant-
hypervirulent clones; their dissemination may mark an evolutionary step toward their 
establishment as major nosocomial pathogens. 
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Legend figure 1: In each column, resistant isolates are shown in black and susceptible ones in grey. ND: ST not determined. CIP: 
ciprofloxacin, LEV: levofloxacin, GEN: gentamycin, AKN: amikacin, TMS: timethoprim-sulfamethoxazole, FOS: fosfomycin, 

























Table 1: Sites of isolation of KPC- K. pneumoniae isolates and clinical features of 
patients 
Total number of isolates: 76  n 




Lower Respiratory Tract  
Rectal swab 












Total number of inpatients: 69 n 




















Wards  Intensive care unit  
Medical wards  
30  
39  






(n)/Age median (range) 25/72 (40 -94) 
44/70 (20-93) 




























A 20 blaKPC-2 Tn4401 2 ΔmgrB locus (n:2) 
25 
(42%) 
B 32 blaKPC-2 Tn3-ISKpn8 6 
g85t (D29Y) (n:2) 
WT (n:3) 


































blaKPC-2 Tn3-ISKpn8 0 - 















F 1 blaKPC-2 Tn3-ISKpn8 0 - 
15 
(1.3%) 
G 1 blaKPC-2 Tn3-ISKpn8 0 - 
101 
(1.3%) 
H 1 blaKPC-2 Tn4401 0 - 
551 
(1.3%) 











WT: Wild type; ND: Not determined 
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